AHA Weighs In on DEA's Telemedicine Prescription Rule
Washington D.C., Wednesday, 19 March 2025.
The AHA supports special registration replacing in-person requirements for telemedicine prescriptions but finds DEA’s proposal burdensome, advocating for streamlined registration and a year for implementation.
Current Regulatory Framework
The Drug Enforcement Administration’s proposed rule, released on January 17, 2025, outlines three distinct types of registration for healthcare providers to replace existing in-person visit requirements for virtual prescribing of controlled substances [1]. Under the proposal, providers would need to obtain state registration for each jurisdiction where they treat patients, significantly expanding regulatory oversight [2].
Industry Response and Concerns
The healthcare industry has responded with measured criticism to the proposed framework. The American Health Care Association and National Center for Assisted Living (AHCA/NCAL) have formally opposed the rule, calling for its rescission and advocating for a more collaborative approach with stakeholders [3]. The proposal’s timing is particularly significant as current telehealth prescription waivers are set to expire in December 2025 [3], creating urgency for a workable solution.
Implementation Challenges
A key concern centers on the DEA’s requirement for providers to review prescription drug monitoring programs across all 50 states and territories within a three-year timeframe [1]. The AHA has emphasized the need for a minimum one-year preparation period following rule finalization to ensure healthcare practitioners can adequately adapt to these new requirements [1]. This timeline consideration is crucial given the complex nature of the proposed changes and their potential impact on healthcare delivery systems.
Future Implications
Healthcare providers and industry organizations are advocating for integration with existing licensure frameworks to streamline the registration process [1]. This approach aims to balance the need for proper oversight of controlled substance prescriptions with the growing demand for accessible telehealth services [2][3]. The outcome of this regulatory process will significantly influence the future landscape of telehealth prescribing practices and healthcare accessibility.